Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
106-120 of 270
SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
Project Oncology®SCNEC Diagnosis: Cytological Clues to a Rare Cervical Malignancy
Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
Project Oncology®Treating Gastrointestinal Neuroendocrine Carcinoma: Beyond Lung-Based Approaches
Diagnosing LCNEC of the Lung: Challenges and Strategies
Project Oncology®Diagnosing LCNEC of the Lung: Challenges and Strategies
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Project Oncology®Personalizing Care for Large Cell Neuroendocrine Carcinoma
From Trials to Real-World Impact: CAR T-Cell Therapy for R/R Large B-Cell Lymphoma
Project Oncology®From Trials to Real-World Impact: CAR T-Cell Therapy for R/R Large B-Cell Lymphoma
Analyzing Toxicity Trends Post-CAR T-Cell Therapy: Implications for Patient Monitoring
Project Oncology®Analyzing Toxicity Trends Post-CAR T-Cell Therapy: Implications for Patient Monitoring
- advertisement
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Project Oncology®DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Gloria’s Story: Her Journey with Indolent Systemic Mastocytosis (ISM)
Medical Industry FeatureGloria’s Story: Her Journey with Indolent Systemic Mastocytosis (ISM)
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Project Oncology®Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Project Oncology®Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Project Oncology®Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Project Oncology®Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
- advertisement
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
Project Oncology®One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
On the Frontlines of Prostate CancerNew Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
On the Frontlines of Prostate CancerWhy Words Matter: Rethinking Terminology in Advanced Prostate Cancer
